Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Microbiota and cancer: In vitro and in vivo models to evaluate nanomedicines

Abstract : Nanomedicine implication in cancer treatment and diagnosis studies witness huge attention, especially with the promising results obtained in preclinical studies. Despite this, only few nanomedicines succeeded to pass clinical phase. The human microbiota plays obvious roles in cancer development. Nanoparticles have been successfully used to modulate human microbiota and notably tumor associated microbiota. Taking the microbiota involvement under consideration when testing nanomedicines for cancer treatment might be a way to improve the poor translation from preclinical to clinical trials. Co-culture models of bacteria and cancer cells, as well as animal cancer-microbiota models offer a better representation for the tumor microenvironment and so potentially better platforms to test nanomedicine efficacy in cancer treatment. These models would allow closer representation of human cancer and might smoothen the passage from preclinical to clinical cancer studies for nanomedicine efficacy.
Type de document :
Article dans une revue
Liste complète des métadonnées

https://hal.univ-angers.fr/hal-03129847
Contributeur : Laurent Lemaire <>
Soumis le : mercredi 3 février 2021 - 10:16:01
Dernière modification le : jeudi 4 février 2021 - 03:26:41

Identifiants

Collections

Citation

Abdallah Ladaycia, Brigitta Loretz, Catherine Passirani, Claus-Michael Lehr, Elise Lepeltier. Microbiota and cancer: In vitro and in vivo models to evaluate nanomedicines. Advanced Drug Delivery Reviews, Elsevier, 2021, 170, pp.44-70. ⟨10.1016/j.addr.2020.12.015⟩. ⟨hal-03129847⟩

Partager

Métriques

Consultations de la notice

22